Literature DB >> 22825819

Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.

Bin Yu1, Yan Zhou, Hao Wu, Zhen Wang, Yang Zhan, Xiao Feng, Ranshen Geng, Yongge Wu, Wei Kong, Xianghui Yu.   

Abstract

Human adenoviruses have been used to develop candidate HIV vaccine vectors, but a major obstacle to the use of vectors derived from Ad5 and other common serotypes is the high prevalence of neutralizing antibodies (NAbs) in humans. Prior studies have reported a prevalence of Ad5 between 60% and 70% in Europe and US, and up to 98% in surveyed African and Asian (Thai) tropical countries. However, few studies have reported on the Ad5 prevalence in Chinese populations. In this study, a total of 1,250 healthy adult serum samples from six administratively separate regions of China were screened by high-throughput luciferase-based virus neutralization assays. Results showed that overall 72% of healthy adults were Ad5 seropositive, and 46.4% with baseline Ad5 NAb titers of >200 in China. Comprehensive analysis by geographical region and age showed that the seroprevalence of Ad5 in southern China such as Guangxi was higher than that in other regions. Geographical differences and climate were considered as the major factors affecting the titer levels of Ad5 in healthy adults. In addition, no apparent gender and ethnic difference was found in any group classified according to region, age, or NAb titer. The present study may provide useful insights for the future development of Ad5-based vaccines and gene therapy.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825819     DOI: 10.1002/jmv.23325

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  21 in total

1.  Mutation in fiber of adenovirus serotype 5 gene therapy vector decreases liver tropism.

Authors:  Zhen Wang; Baoming Wang; Junfang Lou; Jingyi Yan; Lei Gao; Ranshen Geng; Bin Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.

Authors:  Delphine C Malherbe; Jason Mendy; Lo Vang; Philip T Barnette; Jason Reed; Samir K Lakhashe; Joshua Owuor; Johannes S Gach; Alfred W Legasse; Michael K Axthelm; Celia C LaBranche; David Montefiori; Donald N Forthal; Byung Park; James M Wilson; James H McLinden; Jinhua Xiang; Jack T Stapleton; Jonah B Sacha; Barton F Haynes; Hua-Xin Liao; Ruth M Ruprecht; Jonathan Smith; Marc Gurwith; Nancy L Haigwood; Jeff Alexander
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 3.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

4.  Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.

Authors:  Haisu Yi; Qian Wang; Jiankai Deng; Hengchun Li; Yingkun Zhang; Zhilong Chen; Tianxin Ji; Wenming Liu; Xuehua Zheng; Qinghua Ma; Xinxin Sun; Yudi Zhang; Xuegao Yu; Mengzhang He; Ling Chen; Ying Feng
Journal:  Virol Sin       Date:  2022-06-25       Impact factor: 6.947

Review 5.  COVID-19 vaccine development: milestones, lessons and prospects.

Authors:  Maochen Li; Han Wang; Lili Tian; Zehan Pang; Qingkun Yang; Tianqi Huang; Junfen Fan; Lihua Song; Yigang Tong; Huahao Fan
Journal:  Signal Transduct Target Ther       Date:  2022-05-03

6.  Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2013-08-19       Impact factor: 4.939

7.  Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China.

Authors:  Xiang Wang; Man Xing; Chao Zhang; Yong Yang; Yudan Chi; Xinying Tang; Hongbo Zhang; Sidong Xiong; Luogang Yu; Dongming Zhou
Journal:  Emerg Microbes Infect       Date:  2014-05-07       Impact factor: 7.163

8.  The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China.

Authors:  Dao Huang; Marie Hennequi; Alexei Elvachev; Thierry Menguy; Nathalie Silvestre; DeMin Yu; Yue Han; Geneviève Inchauspé; Xinxin Zhang; Ren Zhu
Journal:  Arch Virol       Date:  2015-01-24       Impact factor: 2.574

9.  Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.

Authors:  Kseniya S Yurchenko; Alexandra V Glushchenko; Marina A Gulyaeva; Yuhai Bi; Jianjun Chen; Weifeng Shi; Lyubov S Adamenko; Alexander M Shestopalov
Journal:  Viruses       Date:  2021-03-25       Impact factor: 5.048

10.  A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.

Authors:  Bin Yu; Zhen Wang; Jianing Dong; Chu Wang; Lina Gu; Caijun Sun; Wei Kong; Xianghui Yu
Journal:  Virol J       Date:  2012-11-23       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.